2023 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦ 31Â÷ Çмú´ëȸ ¹× ¿¬¼ö°Á : 2023-07-16
±³À°ÀÏÀÚ : 2023-07-16
±³À°Àå¼Ò : ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç
±³À°ÁÖÁ¦ : 2023 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦ 31Â÷ Çмú´ëȸ ¹× ¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇÑ»êºÎÀΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ
´ã´çÀÚ : ±è¹ÎÁö
¿¬¶ôó : 02-920-5310
À̸ÞÀÏ : kosge2007@empas.com
±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀÎ : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ï / ÇöÀåµî·Ïȸ¿ø50,000 / 60,000ºñȸ¿ø80,000 / 90,000Àü°øÀÇ, ÀüÀÓÀÇ, °£È£»ç40,000 / 50,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 07¿ù 16ÀÏ 08:20~08:50 µî·Ï ()
±âŸ 07¿ù 16ÀÏ 08:50~08:55 °³È¸»ç ±èŹ(°í·ÁÀÇ´ë)
±âŸ 07¿ù 16ÀÏ 08:55~09:00 ÇÁ·Î±×·¥ ¼Ò°³ Á¶½ÃÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 09:00~09:20 »êºÎÀΰú Áúȯ¿¡¼ ¿¢¼ÒÁ» ¿¬±¸ÀÇ ÇöȲ°ú Àü¸Á ÀÌÀÎÇÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 09:20~09:40 ÀӽŠÁß ¸é¿ªÈ°¼ºÈ¿Í ÀÚ¼ÕÀÇ ÀÚÆó½ºÆåÆ®·³Àå¾Ö¿ÍÀÇ ¿¬°ü¼º ³ú½Å°æ°úÇб³½Ç ±èÀºÇÏ(°í·Á´ë)
Åä·Ð 07¿ù 16ÀÏ 09:40~09:50 Discussion ()
ÈÞ½Ä 07¿ù 16ÀÏ 09:50~10:10 Coffee Break ()
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 10:10~10:30 ¿Ü·¡¿¡¼ ÈçÈ÷ º¸´Â 'Cesarean scar niche' ÀÓ»óÀû ÀǹÌ, Áø´Ü°ú °ü¸® Á¶¹®°æ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 10:30~10:50 ¿Ü·¡¿¡¼ 10ºÐ¾È¿¡ ½±°Ô ÇÒ ¼ö ÀÖ´Â ÃֽŠ¿ä½Ç±Ý ¼ö¼ú¹ý ¼Ò°³ µÎÀç±Õ(¼ÒÇÇ¾Æ ¿©¼ºÀÇ¿ø)
Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 10:50~11:00 Discussion ()
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 11:00~11:20 Screening and management of bleeding disorders in adolescents with heavy ÀÌ°æ¿í(°í·ÁÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 11:20~11:40 PMS¿Í PMDD ±×¸®°í menstrual migraineÀÇ Ã³¹æ knowhow. ÀÌ»ç¶ó(¿ï»êÀÇ´ë)
Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 11:40~11:50 Discussion ()
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 11:50~12:10 °æÇÇ¿¡½ºÆ®·Î°ÕÀÇ ÀåÁ¡°ú ÀÓ»óÀû¿ë ¹ÚÇöÅÂ(°í·ÁÀÇ´ë)
½Ä»ç 07¿ù 16ÀÏ 12:10~13:00 Á¡½É½Ä»ç ()
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 13:00~13:10 Analysis of Obstetrics and Gynecology Outpatient and Inpatient Utilization Rates among Women with disabilities in Korea: the National Health Insurance Service-National Sample Cohort Study Á¤Çý°æ (°í·ÁÀÇ´ë )
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 13:10~13:20 Efficacy of Intracorporeal Ultrasonography in Myoma Detection during Robotic Myomectomy ÀÌÁ¤À± (¼¿ïÀÇ´ë )
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 13:20~13:30 Characteristics of endometrial stem cells according to fertility ±èÀ¯Áø,±èÀº¿µ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 13:30~13:40 Efficacy and Safety of use of a pelubiprofen in patients with primary dysmenorrhea: A Multi-center, Randomized, Placebo-controlled, Double-blind, Cross-over, Phase 3 clinical trial Ãß¼ºÇÊ(ÀÎÇÏÀÇ´ë )
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 13:40~13:50 Effects of exosomes derived from eutopic endometrial cells on cell proliferation and the apoptotic pathway in endometriosis and the discovery of novel exosome-related biomarkers for endometriosis ½ÅÀ¯¸®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 13:50~14:00 The effect of sclerotherapy on ovarian reserve in patients with recurrent endometriomas Á¤¿¬¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 14:00~14:20 Àڱ󻸷Áõ ¾à¹°Ä¡·á ¾ðÁ¦±îÁö ÇؾßÇϴ°¡? Á¤À±Áö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 14:20~14:40 ³ÀÓȯÀÚ¿¡¼ Àڱûù±ÙÀ°Áõ °ü¸® ¾î¶»°Ô Çϴ°¡? ±èÀ¯Áø(Ãæ³²ÀÇ´ë)
Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 14:40~14:50 Discussion ()
ÈÞ½Ä 07¿ù 16ÀÏ 14:50~15:10 Coffee Break ()
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 15:10~15:30 ¹Ýº¹À¯»êÀÇ 2022 ESHRE quideline (¹«¾ùÀÌ »õ·Î¿î °ÍÀΰ¡?) ÁÖÁ¾±æ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 15:30~15:50 The 2023 PCOS international evidence-based guideline(ASRM, ESHRE, Androgen Excess and PCOS Society, Endocrine Society, European Society of Endocrinology collaborated): 2018³â°ú ±×´ë·ÎÀÎ °Í°ú ´Þ¶óÁø °ÍÀº? ±èÁøÁÖ(¼¿ïÀÇ´ë)
Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 15:50~16:00 Discussion ()
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 16:00~16:20 Management of postmenopausal osteoporosis: ACOG 2022 guideline (2021 position statemenr of NAMS¿ÍÀÇ Â÷ÀÌÁ¡Àº ¹«¾ùÀΰ¡?) À̵¿¿Á(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 16:20~16:40 2023 Non-hormone therapy position statement of NAMS (2015³â position statement¿Í ¹Ù²ï Á¡Àº ¹«¾ùÀΰ¡?) ÀÌÀº½Ç(¼øõÇâÀÇ´ë)
Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç 16:40~16:50 Discussion ()
±âŸ 07¿ù 16ÀÏ 16:50~17:00 Æóȸ»ç ±èŹ (°í·ÁÀÇ´ë)